What is it about?
This study reveals how Lp(a) affects DM patients and the general population, and the differing discriminative performance for CVD between the DM and general cohorts. The cut-off may be lower, and the corresponding control target at high Lp(a) levels may be more stringent in these patients.
Featured Image
Photo by Andrey Khoviakov on Unsplash
Why is it important?
Although Lp(a) is regarded as an enhanced CVD risk factor beyond LDL control, in Diabetic patients, its real harm was not recognized before, nor was the cut-off for the risk population in DM.
Perspectives
The risk effect may be different between patients with diabetes and the euglycemic cohort. A deeper study will be conducted into the relationship between Lp(a) and diabetes.
Dr. Song Wen
Shanghai Pudong Hospital, Fudan University
Read the Original
This page is a summary of: Enhanced independent discriminative performance of elevated lipoprotein(a) for cardiovascular outcomes in patients with diabetes: a comparative analysis of optimal cutoff values, Frontiers in Endocrinology, April 2026, Frontiers,
DOI: 10.3389/fendo.2026.1795181.
You can read the full text:
Resources
Contributors
The following have contributed to this page
